TRA CỨU
thông tin biểu ghi
  • Bài trích
  • Ký hiệu PL/XG: 616.36
    Nhan đề: Comparison of the long-term efficacy of Tenofovir monotherapy versus Tenofovir and Phyllanthus Amari combination therapy :
DDC 616.36
Nhan đề Comparison of the long-term efficacy of Tenofovir monotherapy versus Tenofovir and Phyllanthus Amari combination therapy : A randomized controlled trial / Huy Chung Ly, Bay Thi Nguyen, Nga Ngoc Cao, Duong Thai Nguyen, Sang Thanh Do
Tóm tắt Introduction: Hepatitis B infection has become a social burden in over the world due to its high prevalence, while the treatments still do not offer the desired effects. Literature showed that combining traditional medicine with modern drugs was able to inhibit the proliferation of the hepatitis B virus, thus making it an effective treatment. To compare the efficacy of Tenofovir monotherapy versus Tenofovir and Phyllanthus Amari combination therapy in chronic hepatitis B patients. Materials and methods: Randomized controlled clinical trial on 200 chronic hepatitis B patients with HBeAg (+); divided into 2 groups: The combination therapy group used Phyllanthus Amari product and Tenofovir for treatment and the monotherapy group with Tenofovir. Results: The serological, biological, and virological responses in the combination therapy group were earlier than those in the monotherapy group. Statistically significant differences in serological responses between the combination therapy versus monotherapy group were achieved from the 3rd (59% versus 33%, p=0.021) to the 18 th month (99% versus 91%, p=0.029). Statistically significant differences in biochemical responses between the combination therapy versus monotherapy group were achieved from the 9th (12% versus 1%, p=0.003) to the 18th month (35% versus 21%, p=0.040). Statistically significant differences in virological response between the combination therapy versus monotherapy group were achieved from the 6th (23% versus 10%, p=0.021) to the 18th month (97% versus 88%, p=0.029). Conclusion: The combination of Tenofovir and the Phyllanthus Amari product is more effective than using only Tenofovir for treatment in chronic hepatitis B patients with HBeAg-positive.
Từ khóa tự do ALT
Từ khóa tự do Tenofovir
Từ khóa tự do Hepatitis B virus
Từ khóa tự do Phyllanthus Amari
Từ khóa tự do HBeAg
Từ khóa tự do HBV DNA
Tác giả(bs) CN Ly, Chung Huy
Tác giả(bs) CN Cao, Ngoc Nga
Tác giả(bs) CN Nguyen,Thi Bay
Tác giả(bs) CN Do, Thanh Sang
Tác giả(bs) CN Nguyen, Thai Duong
Nguồn trích MedPharmRes 2023tr. 99-108 Số: 3 Tập: 7
000 00000nab#a2200000u##4500
00157019
0029
0040DCF173F-5E73-4F49-8A98-8E7AA6CBB258
005202509121422
008250912s vm| eng
0091 0
039|y20250912142246|ztainguyendientu
040 |aACTVN
041 |aeng
044 |avm
082 |a616.36
245 |aComparison of the long-term efficacy of Tenofovir monotherapy versus Tenofovir and Phyllanthus Amari combination therapy : |bA randomized controlled trial / |cHuy Chung Ly, Bay Thi Nguyen, Nga Ngoc Cao, Duong Thai Nguyen, Sang Thanh Do
520 |aIntroduction: Hepatitis B infection has become a social burden in over the world due to its high prevalence, while the treatments still do not offer the desired effects. Literature showed that combining traditional medicine with modern drugs was able to inhibit the proliferation of the hepatitis B virus, thus making it an effective treatment. To compare the efficacy of Tenofovir monotherapy versus Tenofovir and Phyllanthus Amari combination therapy in chronic hepatitis B patients. Materials and methods: Randomized controlled clinical trial on 200 chronic hepatitis B patients with HBeAg (+); divided into 2 groups: The combination therapy group used Phyllanthus Amari product and Tenofovir for treatment and the monotherapy group with Tenofovir. Results: The serological, biological, and virological responses in the combination therapy group were earlier than those in the monotherapy group. Statistically significant differences in serological responses between the combination therapy versus monotherapy group were achieved from the 3rd (59% versus 33%, p=0.021) to the 18 th month (99% versus 91%, p=0.029). Statistically significant differences in biochemical responses between the combination therapy versus monotherapy group were achieved from the 9th (12% versus 1%, p=0.003) to the 18th month (35% versus 21%, p=0.040). Statistically significant differences in virological response between the combination therapy versus monotherapy group were achieved from the 6th (23% versus 10%, p=0.021) to the 18th month (97% versus 88%, p=0.029). Conclusion: The combination of Tenofovir and the Phyllanthus Amari product is more effective than using only Tenofovir for treatment in chronic hepatitis B patients with HBeAg-positive.
653 |aALT
653 |aTenofovir
653 |aHepatitis B virus
653 |aPhyllanthus Amari
653|aHBeAg
653|aHBV DNA
700 |aLy, Chung Huy
700 |aCao, Ngoc Nga
700 |aNguyen,Thi Bay
700|aDo, Thanh Sang
700|aNguyen, Thai Duong
7730 |tMedPharmRes |d2023|gtr. 99-108|x2615-9139|v7|i3
890|a0|b0|c1|d0
Không tìm thấy biểu ghi nào